Pre-hospital Administration of Fibrinogen in Trauma-Induced Coagulopathy
Launched by UNIDADE LOCAL DE SAUDE DO ARCO RIBEIRINHO · Aug 30, 2024
Trial Information
Current as of September 08, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of a treatment called fibrinogen concentrate (FC) in adults who have serious injuries and are experiencing major bleeding or are at risk of bleeding. The goal is to see if giving FC before patients reach the hospital can help improve their blood clotting and overall outcomes compared to standard care alone. Researchers will look at the levels of fibrinogen in the blood when patients arrive at the trauma room and check how feasible it is to administer this treatment before getting to the hospital.
To be eligible for this trial, participants must be adults who show signs of a condition called Trauma Induced Coagulopathy (TIC), meaning they have major bleeding or are likely to bleed a lot. Specific criteria include a certain score based on their trauma and shock levels. However, individuals who have certain conditions, such as severe bleeding from only a head injury or known allergies to the treatment, will not be included. If a person joins the trial, they will either receive standard trauma care or standard care plus the fibrinogen concentrate. The trial is not yet recruiting patients, but it aims to help improve treatment options for people with serious bleeding injuries in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Adult patients at risk of Trauma Induced Coagulopathy (TIC), with major bleeding or presumed to be bleeding, identified by TIC criteria: mTICCS score \> 5 or Shock index \> 0.8.
- Exclusion Criteria:
- • Known adverse reactions to fibrinogen concentrate (FC)
- • Isolated trauma such as traumatic head injury only
- • Need for cardiopulmonary resuscitation (CPR) on the scene or peri-arrest scenarios
- • Deep hypothermia
- • Age below 18 years
- • Pregnancy
- • Prothrombin time ratio superior equal or superior to 1.2 (PTr\>1.2) at the hospital admission
- • Refusal to participate (if the patients are capable of consenting)
About Unidade Local De Saude Do Arco Ribeirinho
Unidade Local de Saúde do Arco Ribeirinho is a prominent healthcare institution dedicated to enhancing public health outcomes in the Arco Ribeirinho region. As a clinical trial sponsor, it focuses on advancing medical research and innovation through rigorous scientific studies aimed at evaluating new treatments and interventions. Committed to ethical standards and patient safety, the organization collaborates with healthcare professionals, researchers, and regulatory bodies to ensure the successful execution of clinical trials. Through its initiatives, Unidade Local de Saúde do Arco Ribeirinho aims to contribute significantly to the body of medical knowledge and improve healthcare delivery within the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Pedro Batarda Sena, MD
Principal Investigator
Unidade Local de Saude do Arco Ribeirinho
Francisco Das Neves Coelho, MD
Principal Investigator
Unidade Local de Saude do Arco Ribeirinho
Tiago Quaresma, MD
Principal Investigator
Unidade Local de Saude do Arco Ribeirinho
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported